[Kaixin San ameliorating doxorubicin-induced neurotoxicity by activating AMPK signaling pathway]

Ying-Chao Wu1, Jia-Qi Cui2, Hui Wang2

  • 1State Key Laboratory of Traditional Chinese Medicine Syndrome, the Second Affiliated Hospital of Guangzhou University of Chinese Medicine Guangzhou 510120, China School of Traditional Chinese Medicine, Jinan University Guangzhou 510632, China the Second Clinical Medical College, Guangzhou University of Chinese Medicine Guangzhou 510405, China.

Insights

Kaixin San (KXS) alleviates doxorubicin-induced neurotoxicity by activating the AMPK pathway, reducing neuronal ferroptosis and glial cell immune response. This traditional Chinese medicine intervention offers a novel approach to managing chemotherapy side effects.

Area of Science:

  • Neuroscience
  • Oncology
  • Pharmacology

Context:

  • Doxorubicin chemotherapy is a critical cancer treatment but often causes neurotoxicity.
  • Traditional Chinese Medicine (TCM) offers potential interventions for chemotherapy-induced side effects.
  • Understanding the molecular mechanisms of neurotoxicity is crucial for developing effective treatments.

Purpose:

  • To investigate the pathological mechanisms of doxorubicin-induced neurotoxicity.
  • To evaluate the efficacy of Kaixin San (KXS) in mitigating doxorubicin neurotoxicity.
  • To elucidate the molecular pathways involved in KXS intervention.

Summary:

  • This study utilized BALB/c mice with 4T1 triple-negative breast cancer models to assess doxorubicin chemotherapy and doxorubicin + KXS treatments.
  • Pathological examination, long non-coding RNA sequencing, Western blot, and in vitro models revealed KXS alleviates doxorubicin-induced neuronal degeneration in the prefrontal cortex.
  • KXS intervention is linked to the AMPK signaling pathway, reducing neuronal ferroptosis and glial cell immune response via the AMPK/HIF-1α/ACSL4 pathway.

Impact:

  • Provides mechanistic insights into doxorubicin neurotoxicity and KXS therapeutic effects.
  • Highlights the potential of KXS as an adjuvant therapy to manage chemotherapy-induced neurotoxicity.
  • Identifies the AMPK/HIF-1α/ACSL4 pathway as a key target for neuroprotection during chemotherapy.